Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MMP13 | P45452 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28675585 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2HSD17B10GAALMNAMMP13 | |
| SCHEMBL29808051 | 0.88 | KMT2A (0.55) | SMN1; SMN2GAALMNAMMP13MAPK1 | |
| SCHEMBL23521924 | 0.88 | KMT2A (0.55) | SMN1; SMN2GAALMNAMMP13MAPK1 | |
| SCHEMBL28931232 | 0.86 | KMT2A (0.47) | SMN1; SMN2HSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL23521860 | 0.86 | KMT2A (0.61) | SMN1; SMN2MMP13ALDH1A1CYP3A4HTT | |
| SCHEMBL29819690 | 0.86 | KMT2A (0.61) | SMN1; SMN2MMP13ALDH1A1CYP3A4HTT | |
| SCHEMBL23521747 | 0.85 | CYP2C19 (0.58) | SMN1; SMN2LMNAMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL29536120 | 0.85 | L3MBTL1 (0.56) | SMN1; SMN2LMNACYP3A4MAPK14L3MBTL1 | |
| SCHEMBL29808056 | 0.85 | CYP2C19 (0.58) | SMN1; SMN2LMNAMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL28931229 | 0.85 | L3MBTL1 (0.56) | SMN1; SMN2LMNACYP3A4MAPK14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310955-B2 | Cyclic amide compounds for rabies treatment and method thereof | IRIMAJIRI THERAPEUTICS INC. (JP) | 2025-05-27 | — | — | US | disclosed |
| US-20220331300-A1 | CYCLIC AMIDE COMPOUNDS FOR RABIES TREATMENT AND METHOD THEREOF | IRIMAJIRI THERAPEUTICS INC. (JP) | 2022-10-20 | — | — | US | disclosed |
| EP-3978076-A1 | CYCLIC AMIDE COMPOUNDS FOR RABIES TREATMENT AND METHOD THEREOF | Oita University Institute of Advanced Medicine, Inc. (JP) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331300-A1 | CYCLIC AMIDE COMPOUNDS FOR RABIES TREATMENT AND METHOD THEREOF | F12, RXFP3, AVPR1B | SMN1; SMN2 1288/4885HSD17B10 2184/4885GAA 819/4885 |
| US-12310955-B2 | Cyclic amide compounds for rabies treatment and method thereof | F12, RXFP3, AVPR1B | SMN1; SMN2 1288/4885HSD17B10 2184/4885GAA 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.